www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Allergy immunotherapy
    • Healthcare professionals
      • Reweal
      • Webinars
    • Pipeline
    • Clinical trials
    • Clinical data sharing
  • Our company
    • Newsroom
      • Stories
    • Privacy
    • Global presence
    • Organisation
    • History
    • Owners
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Board of Management
      • Board of Directors
      • Annual general meeting
      • Annual general meeting (DK)
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
      • ADR Programme
    • Contact IR
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

Shareholder information

Links: 
Dividend history
Analyst coverage
Analyst estimates
Shareholder information
Authorizations
ADR Programme

Ownership

On 31 December 2021, ALK had 20,434 registered shareholders versus 17,697 at the end of 2020. The registered shareholders owned 98% of the share capital (98%). Two shareholders have reported to ALK

that they held 5% or more of the shares on 31 December 2021: the Lundbeck Foundation had a 40.3% interest (including A and AA shares) and ATP had a 5.8% interest.

Of the largest registered shareholders, the vast majority were institutional investors, particularly from Europe and North America. The international registered ownership was estimated at approximately 31% (23%), representing 52% of the free float of the B share capital, excluding the Lundbeck Foundation’s holding and treasury shares.

To meet obligations to deliver shares under management incentive programmes, ALK held 148,528 of its own shares, or 1.3% of the share capital, versus 1.9% at the end of 2020. The holding was reduced during the year following the settlement of share option and performance share programmes. The current holding is considered sufficient to cover current obligations under long-term incentive programmes.

The Board of Directors and Board of Management held a total of 12,963 shares at year-end, corresponding to 0.1% of the share capital (0.1%)
 

Major shareholders* and treasury shares as at 31 December 2021

 The Lundbeck Foundation

Registered office: Copenhagen, Denmark

A shares, number: 920,720

AA shares, number: 92,072

B shares number: 3,474,827

Interest: 40.3%

Votes: 67.2%


ATP**

Registered office: Hillerød, Denmark

B shares, number: 642,314

Interest: 5.8%

Votes: 3.2%
 

ALK – own shares

Registered office: Hørsholm, Denmark

B shares, number: 148,528 B shares

Interest: 1.3%

  

* Notified shareholdings of 5% or more of the company's shares

** The Danish Labour Market Supplementary Pension

 
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved